AlzChem

The Alzchem share fell temporarily by double digits to its lowest level since early February and was still down 8.8 percent in the afternoon at €147.40. The stock thus broke out of its sideways movement since the summer. Alzchem confirmed its forecast for 2026, but Berenberg analyst Gerhard Orgonas expects that market estimates for operating profit will have to be revised down by around four to five percent due to accelerated write‑downs on a new nitroguanidine plant. » Mere på finanzen.net

In the third quarter Alzchem’s revenue rose slightly to almost €140.0 million (previous year approx. €137.0 million), while EBITDA fell from €29.7 million to €28.7 million and the margin declined by 1.2 percentage points to 20.5%. Profit decreased from €16.3 million to €13.5 million. The company confirmed its full-year guidance of around €600 million in revenue and about €126 million in EBITDA. In the first nine months, revenues increased 4% to €443.8 million and EBITDA rose 8% to €93.2 million; results were weighed down by higher energy and raw material costs as well as start-up expenses for new capacities. » Mere på finanzen.net

The management board of Alzchem Group, with the supervisory board’s approval, has decided to repurchase up to 125,000 shares over a period of up to 12 months with a total volume of up to €20 million. The shares may be used as acquisition currency, for employee participation programmes, or for cancellation and capital reduction. The buyback will start after the publication of the Q3 figures on 29 October 2026 and after the expiry of the closed period; exact details will be announced before the start. » Mere på finanzen.net